3 ms·
WHO recommends antibody treatment for Covid patients at high risk
- _Microft 5y agoSummary, compiled by reordering and shortening paragraphs from the linked article: "Casirivimab and imdevimab are monoclonal antibodies that when used together bind to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells. [They] probably reduce deaths (ranging from 49 fewer per 1,000 [= -4.9%] in the severely ill to 87 fewer [= -8.9%] in the critically ill) and the need for mechanical ventilation in seronegative patients. For all other covid-19 patients, any benefits of this antibody treatment are unlikely to be meaningful."